BACE1, beta-secretase 1, 23621

N. diseases: 120; N. variants: 8
Disease: Memory impairment ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 AlteredExpression phenotype BEFREE Importantly, we show that restoration of Cav-1 levels in the brains of male <i>db/db</i> mice using adenovirus overexpressing Cav-1 (AAV-Cav-1) rescues learning and memory deficits and reduces pathology (i.e., APP, BACE-1 and p-tau levels). 31527120 2019
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 AlteredExpression phenotype BEFREE Results reveal that SMC 1) reduces oxidative stress and neuro-inflammation; 2) modulates the distribution and levels of several metal ions; 3) decreases amyloid-β peptide (Aβ) generation by inhibiting the expression of its precursor protein APP and β-secretase (BACE1); and 4) attenuates tau hyperphosphorylation and neurofibrillary tangles (NFT) formation via promoting protein phosphatase 2A (PP2A) activity, thereby preserving synaptic proteins and neuron activities and finally improving spatial learning and memory deficits in AD model mice. 29688618 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 AlteredExpression phenotype BEFREE We found that oral treatment with FLDK reversed learning and memory impairment, reduced Aβ burden and expression of β-site amyloid precursor protein cleavage enzyme 1 (BACE1), and decreased microglial activation in senile plaques. 29038004 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 Biomarker phenotype BEFREE An upregulation of the BACE1 pathway appears to participate in both cortical Aβ plaque deposition and memory impairment caused by CSR. 28145081 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 AlteredExpression phenotype BEFREE BAG-1M co-activates BACE1 transcription through NF-κB and accelerates Aβ production and memory deficit in Alzheimer's disease mouse model. 28502705 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 Biomarker phenotype BEFREE We found that MVAD, mostly prenatal MVAD, promotes beta-site APP cleaving enzyme 1 (BACE1)-mediated Aβ production and neuritic plaque formation, and significantly exacerbates memory deficits in AD model mice. 28130638 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 Biomarker phenotype BEFREE The main aim of this study was to assess the influence of subchronic (28-fold) administration of Salvia miltiorrhiza root extract (SE, 200mg/kg, p.o.) on behavioural activity and memory of rats and to evaluate the activities of cholinesterases (AChE and BuChE) and gene expression levels of AChE and BuChE as well as of beta-secretase (BACE1) in the hippocampus and frontal cortex in vivo.Huperzine A (HU, 0.5mg/kg b.w., p.o.) served as a positive control substance, whereas scopolamine (0.5mg/kg, i.p.) injection was used as a well-known model of memory impairment. 28219697 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 Biomarker phenotype BEFREE Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease. 29078331 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 AlteredExpression phenotype BEFREE Our results showed that curcumin administration (150 or 300 mg/kg/day, intragastrically, for 60 days) dramatically reduced Aβ production by downregulating BACE1 expression, preventing synaptic degradation, and improving spatial learning and memory impairment of 5×FAD mice. 26910813 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 Biomarker phenotype BEFREE Here, I review recent progress in preclinical studies that have evaluated the efficacies and potential limitations of genetic/pharmacological inhibition of BACE1, with special focus on AD-associated phenotypes including synaptic dysfunction, neuron loss and memory deficits in animal models. 27093940 2016
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 Biomarker phenotype BEFREE However, recent investigations using genetic animal models raise concern that therapeutic BACE1 inhibition may encounter the dramatic reduction of efficacy in ameliorating AD-like pathology and memory deficits during disease progression. 25523425 2015
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 Biomarker phenotype BEFREE Here, we demonstrated that treadmill exercise (TE) prevented PS2 mutation-induced memory impairment and reduced Aβ-42 deposition through the inhibition of β-secretase (BACE-1) and its product, C-99 in cortex and/or hippocampus of aged PS2 mutant mice. 23907580 2013
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 AlteredExpression phenotype BEFREE Our recent report showed that genetic inhibition of TNFα/TNF receptor signal transduction down-regulates β amyloid cleavage enzyme 1 (BACE1) activity, reduces Aβ generation and improves learning and memory deficits. 23405115 2013
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 AlteredExpression phenotype BEFREE These data provide evidence for regulation of BACE1 expression and AD pathogenesis by GSK3β and that inhibition of GSK3 signaling can reduce Aβ neuropathology and alleviate memory deficits in AD model mice. 23202730 2013
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 AlteredExpression phenotype BEFREE Here we show that overexpression of 12/15-LO leads to increased levels of β-secretase-1 (BACE1) mRNA and protein, a significant elevation in Aβ levels and deposition, and a worsening of memory deficits in AD transgenic mice. 22275252 2012
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 Biomarker phenotype BEFREE 7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease. 21900882 2012
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 AlteredExpression phenotype BEFREE In Tg2576 mice, knockdown by short hairpin RNA or knockout of the S100a9 gene significantly reduced the neuropathology, greatly improved the learning and memory impairment and reduced the amount of Aβ and APP-CTs by increasing neprilysin and decreasing BACE activity. 22301734 2012
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 AlteredExpression phenotype BEFREE BACE1 and cathepsin B (CatB) proteases have β-secretase activity, but gene knockout studies have not yet validated that the absence of these proteases improves memory deficits in such an animal model. 22337825 2012
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 Biomarker phenotype BEFREE Therefore, lowering Abeta levels by BACE1 manipulations represents a key therapeutic strategy, but it remains unclear whether partial inhibition of BACE1, as expected for AD treatments, can improve memory deficits. 20089133 2010
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 Biomarker phenotype BEFREE Our findings thus demonstrated that the natural product TDC as a new BACE1 inhibitor could ameliorate memory impairment in mice, and is expected to be potentially used as a lead compound for further anti-AD reagent development. 20412384 2010
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 Biomarker phenotype BEFREE Importantly, BACE1(+/-) deletion was no longer able to rescue memory deficits or cholinergic neurodegeneration in 5XFAD mice at the advanced stage. 20886088 2010
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 GeneticVariation phenotype BEFREE Importantly, BACE1 gene deletion also rescues memory deficits in 5XFAD mice. 17258906 2007
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.100 AlteredExpression phenotype BEFREE TNFR1 regulates BACE1 promoter activity via the nuclear factor-kappaB pathway, and the deletion of TNFR1 in APP23 transgenic mice prevents learning and memory deficits. 17724122 2007